| Pharmaceutical Information |
| Drug Name |
Hydroxyzine pamoate |
| Drug ID |
BADD_D01113 |
| Description |
Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus.[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.[A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677] |
| Indications and Usage |
Hydroxyzine is indicated for the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested.[L9677] It is also indicated in the treatment of histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria.[L9677]
Canadian labeling states that hydroxyzine is also indicated in adults and children as a premedication prior to medical procedures, such as dental surgery.[L9680] It is also used in the control of nausea and vomiting, excluding nausea and vomiting of pregnancy.[L9680] |
| Marketing Status |
approved |
| ATC Code |
N05BB01 |
| DrugBank ID |
DB00557
|
| KEGG ID |
D01096
|
| MeSH ID |
D006919
|
| PubChem ID |
25096
|
| TTD Drug ID |
D0O6SX
|
| NDC Product Code |
49711-1508; 50090-5934; 68788-8119; 71205-558; 0615-8420; 0115-1804; 55154-2127; 63629-9612; 71205-087; 71335-1265; 72189-009; 82982-032; 70518-0209; 70518-3194; 70518-3311; 71205-123; 71205-433; 71205-483; 71335-1058; 71335-1714; 71335-2187; 63187-763; 49452-3659; 66022-0122; 68071-4954; 71335-2076; 0615-8419; 51927-2316; 70518-1411; 70934-962; 71610-095; 71610-239; 72189-480; 43063-406; 43353-094; 0185-0674; 50090-4385; 60687-696; 63629-9244; 67296-0222; 68071-2573; 68788-7767; 70518-1150; 72189-315; 0069-5410; 14539-674; 0185-0676; 50090-0374; 50268-399; 51655-725; 51655-847; 59762-5420; 63629-8874; 68071-2521; 68788-8111; 70518-0500; 70518-2350; 70518-2769; 70518-3232; 0555-0302; 71335-1923; 13746-111; 0904-7065; 0069-5420; 0185-0615; 50268-398; 60687-707; 68071-2255; 70518-1504; 70518-2296; 70518-3323; 0555-0324; 71335-0998; 71335-1325; 71610-217; 69237-003; 14539-675; 0115-1803; 55154-2337; 61919-880; 68084-847; 70518-3452; 0555-0323; 51604-0004; 43063-172; 43353-199; 50090-0355; 51655-252; 55700-860; 58118-0025 |
| UNII |
M20215MUFR
|
| Synonyms |
Hydroxyzine | 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol | Hydroxyzine Dihydrochloride | Vistaril | Hydroxyzine Pamoate | Pamoate, Hydroxyzine | Orgatrax | Durrax | Atarax | Hydroxyzine Hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C44H43ClN2O8 |
| CAS Registry Number |
10246-75-0 |
| SMILES |
C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC
4=CC=CC=C43)C(=O)O)O)O)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
